Diabetes Management Guidelines
American Diabetes Association (ADA) 2013 Guidelines
Updated recommendations are available. Click here.
Source: American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(suppl 1):S11-S66.
Jump to a section or click the arrow at the bottom right of each section
Diabetes and Hypertension :: Goals and Treatment Updated recommendations are available. Click here.
- Measure BP at all routine visits; confirm elevated BP at separate visit
- <140 mm Hg systolic for persons with diabetes and hypertension
- Lower targets (such as <130 mm Hg) may be appropriate in certain patients if target can be achieved without treatment burden
- <80 mm Hg diastolic for patients with diabetes
- BP ≥120/80 mm Hg
- Lifestyle changes: weight loss (if overweight), DASH-style diet including sodium restrictions, moderation of alcohol intake, increased physical activity
- BP ≥140/80 mm Hg
- Lifestyle changes
- Pharmacologic therapy
- ACEI or ARB for persons with diabetes and hypertension
- ≥2 agents at maximal doses usually required to achieve BP targets
- Administer ≥1 agent at bedtime
- Monitor serum creatinine/eGFR and serum potassium if using ACEI, ARB, or diuretic
- Pregnant women with diabetes and hypertension
- 110–129/65–79 mm Hg target goal
- ACEI, ARBs contraindicated
ADA Guidelines: Hypertension and Blood Pressure Control (1 of 2)
ADA Guidelines: Hypertension and Blood Pressure Control (2 of 2)
ADA Guidelines: Glycemic, Blood Pressure, and Lipid Control
ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; BP=blood pressure; DASH=Dietary Approaches to Stop Hypertension; eGFR=estimated glomerular filtration rate
The pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual package inserts for use outside of the United States.
This content was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.